Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.35 |
| ▸ | WNT1 | P04628 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 5/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316586 | 0.90 | CREBBP (0.36) | CREBBPUSP30RETFGFR3ATM | |
| SCHEMBL29471215 | 0.87 | CREBBP (0.40) | CREBBPUSP30FGFR3ATM | |
| SCHEMBL24316602 | 0.87 | CREBBP (0.40) | CREBBPUSP30FGFR3ATM | |
| SCHEMBL31496193 | 0.86 | RET (0.42) | USP30RET | |
| SCHEMBL29471231 | 0.84 | CREBBP (0.37) | CREBBPUSP30RETATM | |
| SCHEMBL26108147 | 0.84 | CREBBP (0.37) | CREBBPUSP30RETATM | |
| SCHEMBL24316600 | 0.83 | CREBBP (0.37) | CREBBPUSP30RETATM | |
| SCHEMBL26113389 | 0.82 | CREBBP (0.36) | CREBBPUSP30RETFGFR3ATM | |
| SCHEMBL30480849 | 0.82 | CREBBP (0.36) | CREBBPUSP30RETFGFR3ATM | |
| SCHEMBL24316575 | 0.82 | USP30 (0.36) | CREBBPUSP30ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | CHEK1 1163/4885CREBBP 2932/4885USP30 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.